-
Mashup Score: 0
Frailty among patients with systemic sclerosis significantly increases the risk for mortality by nearly 10-fold, but shows the potential to improve over time, according to data published in Clinical Rheumatology. “There has been a growing burden of evidence recently in the wider literature about the importance of frailty as a determinant of outcome in chronic disease,” Jessica L.
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 4Duloxetine, milnacipran and pregabalin improve fibromyalgia pain for one in 10 patients - 14 hour(s) ago
Duloxetine, milnacipran and pregabalin can yield significant pain relief over at least 12 weeks for approximately one out of 10 adults with fibromyalgia, according to an analysis of Cochrane reviews published in Rheumatology. “Pharmacological interventions are recommended as part of a multidisciplinary approach combined with physical and/or cognitive interventions for severe forms of
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
💊 Duloxetine, milnacipran and pregabalin can relieve #pain for a small proportion of adults with #fibromyalgia Here's a rundown on the data published in @RheumJnl 👇 https://t.co/3oRS4IRN0S
-
-
Mashup Score: 0Acetaminophen increases risk for hypertension, GI bleeding in patients 65 years and older - 1 day(s) ago
Patients aged 65 years and older who use acetaminophen demonstrate greater risks for serious complications, including hypertension, chronic kidney disease and gastrointestinal bleeding, noted a study published in Arthritis Care & Research. “Almost all clinical guidelines advocate acetaminophen as the first-line oral pharmacological treatment for pain due to osteoarthritis, mainly
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
📝"These data further challenge whether #acetaminophen should be retained as the first-line oral analgesic, especially in older people for common chronic painful conditions" More on the study out of @UniofNottingham ⬇️ https://t.co/4OUpxoie2C
-
-
Mashup Score: 1Colchicine curbs cardiovascular event risk when used with urate-lowering therapy for gout - 2 day(s) ago
Colchicine for gout flare prophylaxis reduces the risk for cardiovascular events among patients initiating urate-lowering therapy, according to data published in The Lancet Rheumatology. “Cardiovascular events have been previously reported to be temporally associated with recent previous gout flares (ie, those within the previous 60 days),” Edoardo Cipolletta, MD, an international
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
💊 #Gout patients taking colchicine with urate-lowering therapy had a weighted hazard ratio of 0.82 (95% CI, 0.69-0.94) for cardiovascular events vs. no colchicine More on the data out of @UniofNottingham ⬇️ https://t.co/Y7Ujoi41fd
-
-
Mashup Score: 1Direct switch from TNFi to tofacitinib shows ‘acceptable’ safety in psoriatic arthritis - 3 day(s) ago
For patients with psoriatic arthritis, switching directly from adalimumab to tofacitinib with no washout period presents no increased safety risks, according to data published in Arthritis Research & Therapy. “There are no available data from randomized controlled trials in PsA assessing clinical outcomes in patients who have directly switched from [TNF inhibitors] to tofacitinib, and
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
🔃Switching directly from #adalimumab to #tofacitinib with no washout period presents no increased safety risks in #PsoriaticArthritis More on the data from Dr. Dafna Gladman @UofT and colleagues ⬇️ https://t.co/XsPWcGjiS7
-
-
Mashup Score: 2
A non-invasive diagnostic model, based partially on saliva samples, distinguished between patients with and without Sjögren’s disease with high sensitivity and specificity, according to data published in Arthritis Research & Therapy. The finding comes as alternatives to minor salivary gland biopsy — a critical, but invasive, step in Sjögren’s diagnosis — are
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
A #Sjogrens diagnostic model based partly on saliva samples showed 📈high sensitivity and specificity 💡The finding comes as alternatives to invasive salivary gland biopsies are increasingly needed, wrote researchers in @ArthritisRes More info ⬇️ https://t.co/ly4lRVFPfS
-
-
Mashup Score: 6
Women with axial spondyloarthritis face longer diagnostic delays and greater disease burden than men despite higher rates of treatment and healthy behaviors, according to data published in International Journal of Rheumatic Diseases. “Although [axial SpA (axSpA)] can affect both males and females, there are differences in gender in terms of prevalence, clinical presentation, disease
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
👩 Women with #axialSpA have an average diagnostic delay 2.4 years longer than men while reporting higher disease activity, greater functional limitation and worse #mentalhealth Check @GoHealio for more on the data ⬇️ https://t.co/tWUK7ntIyD
-
-
Mashup Score: 14New ACR president: Pharmacy benefit managers, artificial intelligence ‘must be regulated’ - 7 day(s) ago
Although artificial intelligence presents “exciting opportunities,” its use in patient care “must be regulated” to address biases in decision making, said newly appointed American College of Rheumatology President Carol Langford, MD, MHS. “The interpretation of AI-provided data needs to be made in the context of each patient’s history, clinical presentation,
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
🗣️ "The ACR is prepared to hit the ground running with the next Congress to reform #PBM practices that hinder patient care" Healio sat down for a Q&A with Dr. Carol Langford, the new president of @ACRheum ⬇️ https://t.co/txTsKFeJ01
-
-
Mashup Score: 1New ACR president: Pharmacy benefit managers, artificial intelligence ‘must be regulated’ - 7 day(s) ago
Although artificial intelligence presents “exciting opportunities,” its use in patient care “must be regulated” to address biases in decision making, said newly appointed American College of Rheumatology President Carol Langford, MD, MHS. “The interpretation of AI-provided data needs to be made in the context of each patient’s history, clinical presentation,
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
🗣️ "The ACR is prepared to hit the ground running with the next Congress to reform #PBM practices that hinder patient care" Healio sat down for a Q&A with Dr. Carol Langford, the new president of @ACRheum ⬇️ https://t.co/txTsKFeJ01
-
-
Mashup Score: 0Ivarmacitinib curbs rheumatoid arthritis symptoms, improves function through 52 weeks - 7 day(s) ago
A once-daily dose of ivarmacitinib reduced disease activity and improved function among patients with rheumatoid arthritis through 52 weeks, according to phase 3 trial results published in Annals of the Rheumatic Diseases. “Ivarmacitinib (formerly SHR0302), an orally administered, highly selective JAK1 inhibitor, exhibits potency and selectivity for JAK1 that is over 10-fold for JAK2,
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
💊 A once-daily dose of #ivarmacitinib reduced disease activity and improved function among patients with #RheumatoidArthritis through 52 weeks More on the data in @eular_ARD ⬇️ https://t.co/ssglAbMyfl
-
😟 #SystemicSclerosis patients who qualified as "frail" had 📈10x the mortality risk in a study from Dr. Jessica Fairley @StVincentsMelb and colleagues 💡 However, there may be "an important window to intervene with simple strategies"... Learn more ⬇️ https://t.co/6XiCcajERk